Amylyx Pharmaceuticals Inc (AMLX)vsZoetis Inc (ZTS)
AMLX
Amylyx Pharmaceuticals Inc
$29.86
-6.10%
HEALTHCARE · Cap: $4.09B
ZTS
Zoetis Inc
$82.96
+0.47%
HEALTHCARE · Cap: $33.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates -1427769% more annual revenue ($9.49B vs $-665,000). ZTS leads profitability with a 26.4% profit margin vs 0.0%. ZTS earns a higher WallStSmart Score of 56/100 (C).
AMLX
Avoid33
out of 100
Grade: F
ZTS
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AMLX.
Margin of Safety
+11.2%
Fair Value
$144.94
Current Price
$82.96
$61.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 75 in profit
Strong operational efficiency at 38.2%
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Trading at 10.2x book value
Expensive relative to growth rate
Revenue declined 1.3%
Earnings declined 11.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
The strongest argument for AMLX centers on Debt/Equity, Altman Z-Score.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 26.4% and operating margin at 38.2%.
Bear Case : AMLX
The primary concerns for AMLX are EPS Growth, Profit Margin, Operating Margin.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, PEG Ratio, Revenue Growth. Debt-to-equity of 2.80 is elevated, increasing financial risk.
Key Dynamics to Monitor
AMLX profiles as a value stock while ZTS is a declining play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.68 — expect wider price swings.
ZTS is growing revenue faster at -1.3% — sustainability is the question.
ZTS generates stronger free cash flow (717M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (56/100 vs 33/100), backed by strong 26.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, employs a unique neuroprotective mechanism that has shown significant potential in improving patient outcomes in clinical trials. With a robust pipeline and a dedicated team of neurology experts, Amylyx is well-positioned to tackle substantial unmet medical needs in the neurodegenerative space, making it an attractive investment opportunity for institutional investors seeking to support advancements in critical healthcare solutions.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?